Gene info: ID 1029

Gene: CDKN2A

GENE ID: 1029

Synonyms: ARF|CDK4I|CDKN2|CMM2|INK4|INK4A|MLM|MTS-1|MTS1|P14|P14ARF|P16|P16-INK4A|P16INK4|P16INK4A|P19|P19ARF|TP16

Description: cyclin dependent kinase inhibitor 2A

Gene type: protein-coding

Location: 9p21.3

dbXrefs: Ensembl:ENSG00000147889 MIM:600160 Vega:OTTHUMG00000019686 UniprotKB:P42771

RefSeq: NG_007485.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: OD|ND

# Publications: 57

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 9.240e-1 (AD) 4.052e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
RHOG	0.711
SYNGR2	0.697
RRBP1	0.692
PLEKHF1	0.691
TNIP2	0.665
GDNF	0.664
MVP	0.663
TNFAIP6	0.659
ADA	0.658
LMNA	0.657

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MARCH4	-0.442
NDST3	-0.437
KCNQ4	-0.433
DOK6	-0.423
ANO3	-0.421
MMP24	-0.419
SHANK2	-0.418
EPB41L4B	-0.414
SLC1A6	-0.413
CNGB1	-0.412

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of CDKN2A mRNA"	21346803
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of CDKN2A mRNA]	12710931
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CDKN2A mRNA"	23313794
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CDKN2A protein"	23313794
C494914	3,5,3',4',5'-pentamethoxystilbene	"3,5,3',4',5'-pentamethoxystilbene results in increased expression of CDKN2A mRNA"	19916542
C494914	3,5,3',4',5'-pentamethoxystilbene	"3,5,3',4',5'-pentamethoxystilbene results in increased expression of CDKN2A protein"	19916542
C091768	3'-methoxy-4'-nitroflavone	3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of CDKN2A mRNA]	15111621
C091768	3'-methoxy-4'-nitroflavone	3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of CDKN2A protein]	15111621
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA"	27188386
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	[Tetrachlorodibenzodioxin co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in decreased expression of CDKN2A mRNA	21167638
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	[Tetrachlorodibenzodioxin co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in decreased expression of CDKN2A protein	21167638
C075773	4-phenylbutyric acid	[4-phenylbutyric acid co-treated with decitabine] results in increased expression of CDKN2A mRNA	17210717
C012606	4-vinyl-1-cyclohexene dioxide	4-vinyl-1-cyclohexene dioxide results in increased expression of CDKN2A mRNA	20829426
C580598	5-OH-BDE-47	5-OH-BDE-47 results in decreased expression of CDKN2A mRNA	26988655
C471843	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine results in increased expression of CDKN2A protein	15958644
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA"	27188386
C560597	6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide	"6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide inhibits the reaction [methoxyacetic acid results in increased expression of CDKN2A protein]"	21573189
D000082	Acetaminophen	Acetaminophen results in decreased expression of CDKN2A mRNA	26690555
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of CDKN2A gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of CDKN2A mRNA	28965971
D000395	Air Pollutants, Occupational	"Air Pollutants, Occupational results in decreased methylation of CDKN2A promoter"	26410583
D000517	alpha-Chlorohydrin	alpha-Chlorohydrin analog results in increased expression of CDKN2A protein	26072098
D000517	alpha-Chlorohydrin	alpha-Chlorohydrin results in increased expression of CDKN2A protein	26072098
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of CDKN2A mRNA	16483693
D000643	Ammonium Chloride	Ammonium Chloride results in increased expression of CDKN2A protein	16483693
D001149	Arsenates	Arsenates results in increased expression of CDKN2A mRNA	12773770
D001151	Arsenic	Arsenic affects the expression of CDKN2A protein	17450239
D001151	Arsenic	Arsenic results in decreased expression of CDKN2A mRNA	23872714
D001151	Arsenic	Arsenic results in increased expression of CDKN2A mRNA	12773770
D001151	Arsenic	Arsenic results in increased methylation of CDKN2A gene	24525453
D001151	Arsenic	Arsenic results in increased methylation of CDKN2A promoter	16251483\|2246622
D001151	Arsenic	Arsenic results in increased methylation of CDKN2A promoter alternative form	23073540
D001151	Arsenic	Arsenic results in decreased expression of CDKN2A mRNA	22843710
D001151	Arsenic	Arsenic results in decreased expression of CDKN2A protein	22843710
D001151	Arsenic	BMI1 protein promotes the reaction [Arsenic results in decreased expression of CDKN2A mRNA]	22843710
D001151	Arsenic	BMI1 protein promotes the reaction [Arsenic results in decreased expression of CDKN2A protein]	22843710
D001151	Arsenic	SUZ12 protein promotes the reaction [Arsenic results in decreased expression of CDKN2A mRNA]	22843710
D001151	Arsenic	SUZ12 protein promotes the reaction [Arsenic results in decreased expression of CDKN2A protein]	22843710
D001152	Arsenicals	Arsenicals results in decreased expression of CDKN2A mRNA	23073540
D001152	Arsenicals	Arsenicals results in increased methylation of CDKN2A promoter alternative form	23073540
D001152	Arsenicals	AS3MT gene polymorphism affects the reaction [Arsenicals results in increased methylation of CDKN2A promoter alternative form]	23073540
C006632	arsenic trioxide	[arsenic trioxide co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CDKN2A mRNA	18922899
C006632	arsenic trioxide	arsenic trioxide promotes the reaction [decitabine results in increased expression of CDKN2A mRNA]	16613325
C006632	arsenic trioxide	arsenic trioxide results in decreased methylation of CDKN2A gene	15191659
C006632	arsenic trioxide	[arsenic trioxide results in decreased methylation of CDKN2A gene] which results in increased expression of CDKN2A mRNA	20416177\|2041617
C006632	arsenic trioxide	arsenic trioxide results in decreased methylation of CDKN2A promoter	16008847\|1661332
C006632	arsenic trioxide	[arsenic trioxide results in decreased methylation of CDKN2A promoter] which results in increased expression of CDKN2A mRNA	16613325\|1661332
C006632	arsenic trioxide	arsenic trioxide results in increased expression of and affects the localization of CDKN2A protein	16613325
C006632	arsenic trioxide	arsenic trioxide results in increased expression of CDKN2A gene	21544632
C006632	arsenic trioxide	arsenic trioxide results in increased expression of CDKN2A mRNA	12864950\|1519165
C006632	arsenic trioxide	arsenic trioxide results in increased expression of CDKN2A protein	15191659
C006632	arsenic trioxide	decitabine promotes the reaction [arsenic trioxide results in increased expression of CDKN2A mRNA]	16613325
C006632	arsenic trioxide	GH1 protein promotes the reaction [arsenic trioxide results in increased expression of CDKN2A mRNA]	23851143
C015001	arsenite	arsenite results in decreased expression of CDKN2A mRNA	21040761
C015001	arsenite	arsenite results in decreased expression of CDKN2A protein	21040761
C015001	arsenite	arsenite results in decreased methylation of CDKN2A promoter	23974009
C015001	arsenite	arsenite results in increased methylation of CDKN2A gene	21040761
C015001	arsenite	decitabine inhibits the reaction [arsenite results in decreased expression of CDKN2A protein]	21040761
C015001	arsenite	U 0126 inhibits the reaction [arsenite results in decreased expression of CDKN2A protein]	21040761
C039726	artesunate	CDKN2A protein results in decreased susceptibility to artesunate	20144594
D001194	Asbestos	Asbestos results in decreased expression of CDKN2A mRNA	22076105
D001194	Asbestos	Asbestos results in increased methylation of CDKN2A promoter	15911247
D001194	Asbestos	Asbestos results in increased mutagenesis of CDKN2A gene	19375815
D017639	Asbestos, Amosite	"Asbestos, Amosite results in decreased expression of CDKN2A mRNA"	29112861
D017639	Asbestos, Amosite	"Asbestos, Amosite results in decreased expression of CDKN2A mRNA alternative form"	29112861
D017639	Asbestos, Amosite	"Asbestos, Amosite results in decreased expression of CDKN2A protein"	29112861
D017639	Asbestos, Amosite	"Asbestos, Amosite results in decreased expression of CDKN2A protein alternative form"	29112861
D017639	Asbestos, Amosite	"Asbestos, Amosite results in increased methylation of CDKN2A exon"	29112861
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in decreased expression of CDKN2A protein"	21570478
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in decreased expression of CDKN2A protein alternative form"	21570478
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in decreased expression of CDKN2A mRNA alternative form"	19223589
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in decreased expression of CDKN2A protein alternative form"	19223589
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite results in increased mutagenesis of CDKN2A gene alternative form"	19223589
D017638	Asbestos, Crocidolite	"CDKN2A gene mutant form results in increased susceptibility to Asbestos, Crocidolite"	21526190
D017638	Asbestos, Crocidolite	"CDKN2A mRNA alternative form affects the susceptibility to Asbestos, Crocidolite"	19223589
D017638	Asbestos, Crocidolite	"[CDKN2A mRNA alternative form affects the susceptibility to Asbestos, Crocidolite] which affects the expression of FAF1 mRNA"	19223589
D001205	Ascorbic Acid	Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of CDKN2A protein]	21621607
D001374	Azacitidine	Azacitidine affects the methylation of CDKN2A gene	18443271
D001374	Azacitidine	Azacitidine results in decreased metabolism of CDKN2A promoter	15547111
D001374	Azacitidine	Azacitidine results in decreased methylation of CDKN2A gene	17686055
D001374	Azacitidine	Azacitidine results in increased expression of CDKN2A mRNA	15547111
D001374	Azacitidine	Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene]	17686055
D001374	Azacitidine	[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene	21224363
D001374	Azacitidine	[Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA	21224363
D001374	Azacitidine	Azacitidine results in decreased methylation of CDKN2A gene	21224363
D001374	Azacitidine	Azacitidine results in increased expression of CDKN2A mRNA	21224363
D001397	Azoxymethane	Azoxymethane results in decreased expression of CDKN2A mRNA	12189186
D001397	Azoxymethane	Azoxymethane results in decreased expression of CDKN2A protein	12189186
D001397	Azoxymethane	Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]	12189186
D001397	Azoxymethane	Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]	12189186
D001397	Azoxymethane	Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]	12189186
D001397	Azoxymethane	Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]	12189186
D001397	Azoxymethane	Sulindac inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]	12189186
C487081	belinostat	belinostat results in decreased expression of CDKN2A mRNA	19606018
D001554	Benzene	Benzene results in decreased expression of CDKN2A mRNA	20044985
D001554	Benzene	[Benzene results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA	20044985\|2004498
D001554	Benzene	CDKN2A gene polymorphism affects the susceptibility to Benzene	19596022
D001554	Benzene	MDM2 gene polymorphism affects the reaction [CDKN2A gene polymorphism affects the susceptibility to Benzene]	19596022
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in decreased expression of CDKN2A mRNA	26377693
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased mutagenesis of CDKN2A gene	25435355
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the reaction [sodium bichromate results in decreased expression of CDKN2A mRNA]	22613061
D001564	Benzo(a)pyrene	[chromium hexavalent ion co-treated with Benzo(a)pyrene] affects the expression of CDKN2A mRNA	25820237
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of CDKN2A mRNA	19408242\|2006408
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of CDKN2A protein	20064080\|2146774
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of CDKN2A protein	19408242
D001564	Benzo(a)pyrene	[Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of CDKN2A mRNA	19408242
D001564	Benzo(a)pyrene	[Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of CDKN2A protein	19408242
D001564	Benzo(a)pyrene	Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in decreased expression of CDKN2A mRNA]	20064080
D001564	Benzo(a)pyrene	Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in decreased expression of CDKN2A protein]	20064080
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN2A mRNA	20061341
D001608	Beryllium	[Beryllium results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA	11872642\|1187264
C020711	beryllium sulfate	beryllium sulfate results in increased expression of CDKN2A mRNA	17395767
C020711	beryllium sulfate	beryllium sulfate results in increased expression of CDKN2A protein	17395767
D004958	Estradiol	Estradiol results in decreased expression of CDKN2A mRNA	19027819\|2309414
D001622	Betaine	Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]	19642983
C006780	bisphenol A	bisphenol A results in increased expression of CDKN2A protein	22258036
C006780	bisphenol A	bisphenol A results in increased methylation of CDKN2A gene	22258036
C006780	bisphenol A	bisphenol A affects the expression of CDKN2A mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of CDKN2A gene	28505145
C545990	BMS 754807	CDKN2A gene mutant form results in decreased susceptibility to BMS 754807	24986516
D002066	Busulfan	Busulfan results in increased expression of CDKN2A mRNA	14500376
C027561	butylbenzyl phthalate	[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA	28013214
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in decreased expression of CDKN2A protein	14729356
C026105	butylidenephthalide	butylidenephthalide results in increased expression of CDKN2A protein	16987298\|2377034
D020148	Butyric Acid	"Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]"	24792773
D020148	Butyric Acid	"Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]"	24792773
D020148	Butyric Acid	"Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]"	24792773
D002101	Cacodylic Acid	Cacodylic Acid results in decreased methylation of CDKN2A promoter alternative form	23073540
D002101	Cacodylic Acid	Cacodylic Acid results in decreased expression of CDKN2A mRNA	16122865
D002104	Cadmium	Cadmium results in increased methylation of CDKN2A promoter	17938735
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of CDKN2A mRNA alternative form	25448810
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of CDKN2A protein	17938735\|2381132
D019256	Cadmium Chloride	Cadmium Chloride results in increased methylation of CDKN2A promoter alternative form	25448810
D019256	Cadmium Chloride	CDKN2A results in decreased susceptibility to Cadmium Chloride	25448810
D019256	Cadmium Chloride	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of CDKN2A mRNA alternative form]	25448810
D019256	Cadmium Chloride	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of CDKN2A protein]	17938735
D019256	Cadmium Chloride	decitabine inhibits the reaction [Cadmium Chloride results in increased methylation of CDKN2A promoter]	17938735
D019256	Cadmium Chloride	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA	12634122
C055494	caffeic acid phenethyl ester	caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]	20360939
C055494	caffeic acid phenethyl ester	caffeic acid phenethyl ester results in increased expression of CDKN2A protein	15885897
D002122	Calcium Chloride	Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]	12189186
D002122	Calcium Chloride	Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]	12189186
D002185	Cannabidiol	Cannabidiol results in increased expression of CDKN2A mRNA	21542829
D000069287	Capecitabine	Capecitabine results in decreased expression of CDKN2A protein	17904787
D002211	Capsaicin	Capsaicin results in increased expression of CDKN2A mRNA	18533110
D002251	Carbon Tetrachloride	[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of CDKN2A mRNA	23288052
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of CDKN2A mRNA	23288052
D002330	Carmustine	CDKN2A protein results in increased susceptibility to Carmustine	16786135
D002701	Chloramphenicol	Chloramphenicol results in increased expression of CDKN2A protein	15905168
C034944	chromic acid	chromic acid results in decreased expression of CDKN2A mRNA	27005777
C034944	chromic acid	chromic acid results in increased methylation of CDKN2A gene	27005777
C023600	chromic oxide	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA	12634122
D002857	Chromium	Chromium affects the methylation of CDKN2A protein	16828922
D002857	Chromium	Chromium results in decreased expression of CDKN2A protein	16828922
C074702	chromium hexavalent ion	chromium hexavalent ion results in increased expression of CDKN2A mRNA	23940686
C074702	chromium hexavalent ion	[chromium hexavalent ion co-treated with Benzo(a)pyrene] affects the expression of CDKN2A mRNA	25820237
C074702	chromium hexavalent ion	Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of CDKN2A protein]	21621607
C074702	chromium hexavalent ion	chromium hexavalent ion results in increased expression of CDKN2A protein	21621607
C017133	chromous chloride	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA	12634122
D002995	Clofibric Acid	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of CDKN2A mRNA	17602206
D003033	Coal Tar	Coal Tar results in decreased expression of CDKN2A mRNA	27858113
D003300	Copper	Copper results in decreased expression of CDKN2A protein	16246896
D003300	Copper	[Copper results in increased activity of TP53 protein] which results in increased expression of CDKN2A mRNA	16391388
D019327	Copper Sulfate	Copper Sulfate results in increased expression of CDKN2A mRNA	19549813
C058120	cordycepin	cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]	23690541
D003345	Corticosterone	Corticosterone results in decreased expression of CDKN2A mRNA	15755911
D003474	Curcumin	Curcumin results in decreased expression of CDKN2A protein	17148446
D003474	Curcumin	Curcumin results in increased expression of CDKN2A protein	18156803
D003513	Cycloheximide	Cycloheximide results in increased expression of CDKN2A mRNA	17257637
D003630	Daunorubicin	Daunorubicin affects the expression of CDKN2A mRNA	12656675
D003634	DDT	DDT results in decreased expression of CDKN2A mRNA alternative form	25410620
D003634	DDT	DDT results in decreased expression of CDKN2A protein alternative form	25410620
D003634	DDT	DDT results in increased methylation of CDKN2A promoter alternative form	25410620
C014347	decitabine	[4-phenylbutyric acid co-treated with decitabine] results in increased expression of CDKN2A mRNA	17210717
C014347	decitabine	arsenic trioxide promotes the reaction [decitabine results in increased expression of CDKN2A mRNA]	16613325
C014347	decitabine	decitabine affects the expression of CDKN2A mRNA	17194187
C014347	decitabine	[decitabine affects the methylation of CDKN2A gene] which affects the expression of CDKN2A mRNA	18410530\|1841053
C014347	decitabine	decitabine affects the methylation of CDKN2A promoter	17571247\|1806975
C014347	decitabine	[decitabine affects the methylation of CDKN2A promoter] which affects the expression of CDKN2A mRNA	18454857\|1845485
C014347	decitabine	[decitabine affects the methylation of HIST3H3 protein] which affects the methylation of CDKN2A gene	18410530
C014347	decitabine	[[decitabine co-treated with scriptaid] affects the methylation of CDKN2A promoter] which affects the expression of CDKN2A mRNA	18813790\|1881379
C014347	decitabine	[decitabine co-treated with trichostatin A] affects the expression of CDKN2A protein	17019711
C014347	decitabine	[decitabine co-treated with trichostatin A] affects the methylation of CDKN2A promoter	18069755
C014347	decitabine	[[decitabine co-treated with trichostatin A] affects the methylation of CDKN2A promoter] which affects the expression of CDKN2A mRNA	18813790\|1881379
C014347	decitabine	decitabine inhibits the reaction [arsenite results in decreased expression of CDKN2A protein]	21040761
C014347	decitabine	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of CDKN2A mRNA alternative form]	25448810
C014347	decitabine	decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of CDKN2A protein]	17938735
C014347	decitabine	decitabine inhibits the reaction [Cadmium Chloride results in increased methylation of CDKN2A promoter]	17938735
C014347	decitabine	decitabine promotes the reaction [arsenic trioxide results in increased expression of CDKN2A mRNA]	16613325
C014347	decitabine	decitabine results in decreased expression of CDKN2A mRNA	19027819
C014347	decitabine	decitabine results in decreased methylation of CDKN2A gene	12859993\|1768605
C014347	decitabine	decitabine results in decreased methylation of CDKN2A promoter	16613325\|1719590
C014347	decitabine	[decitabine results in decreased methylation of CDKN2A promoter] which results in increased expression of CDKN2A mRNA	16613325\|1661332
C014347	decitabine	decitabine results in decreased methylation of CDKN2A protein	19732952
C014347	decitabine	decitabine results in increased expression of CDKN2A mRNA	16367923\|1661332
C014347	decitabine	decitabine results in increased expression of CDKN2A mRNA alternative form	17195906
C014347	decitabine	decitabine results in increased expression of CDKN2A protein	12859993\|1661332
C014347	decitabine	decitabine results in increased phosphorylation of CDKN2A protein	19732952
C014347	decitabine	HSPA9 protein promotes the reaction [decitabine results in increased expression of CDKN2A protein]	17389721
C014347	decitabine	Hydroxyurea inhibits the reaction [decitabine results in decreased methylation of CDKN2A gene]	17686055
C014347	decitabine	PEX19 protein promotes the reaction [decitabine results in increased expression of CDKN2A protein]	17389721
C014347	decitabine	decitabine results in increased expression of CDKN2A mRNA	27915011
D003687	Dehydroepiandrosterone	Dehydroepiandrosterone results in increased expression of CDKN2A protein	16457693
D013759	Dronabinol	Dronabinol results in increased expression of CDKN2A protein	17934890
D013759	Dronabinol	Dronabinol results in increased expression of CDKN2A mRNA	21542829
D064791	Desoxycorticosterone Acetate	Desoxycorticosterone Acetate affects the localization of CDKN2A protein	18504326
D064791	Desoxycorticosterone Acetate	Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA	18504326
D064791	Desoxycorticosterone Acetate	Desoxycorticosterone Acetate results in increased expression of CDKN2A protein	18504326
D064791	Desoxycorticosterone Acetate	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]	18504326
D064791	Desoxycorticosterone Acetate	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]	18504326
D064791	Desoxycorticosterone Acetate	Spironolactone inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]	18504326
D064791	Desoxycorticosterone Acetate	Spironolactone inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]	18504326
D003993	Dibutyl Phthalate	[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA	28013214
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in increased expression of CDKN2A mRNA	28962523
D002945	Cisplatin	[Cisplatin co-treated with Quercetin] results in increased expression of CDKN2A mRNA	27514524
D002945	Cisplatin	Cisplatin results in decreased expression of CDKN2A protein	16797627
D002945	Cisplatin	Cisplatin results in increased expression of CDKN2A mRNA	16797627
D002945	Cisplatin	Cisplatin results in increased expression of CDKN2A protein	16797627\|2054095
D018119	Stavudine	Stavudine affects the expression of CDKN2A protein	18389896
D004051	Diethylhexyl Phthalate	[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA	28013214
D004052	Diethylnitrosamine	ATM protein inhibits the reaction [Diethylnitrosamine results in increased expression of CDKN2A protein]	19919837
D004052	Diethylnitrosamine	[Carbon Tetrachloride co-treated with Diethylnitrosamine] results in increased expression of CDKN2A mRNA	23288052
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of CDKN2A protein	15082532
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of CDKN2A mRNA	24535843
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of CDKN2A protein	19919837
D004052	Diethylnitrosamine	[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased expression of CDKN2A mRNA	16317707
D004052	Diethylnitrosamine	[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased expression of CDKN2A protein	16317707
D004052	Diethylnitrosamine	Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]	19642983
D004052	Diethylnitrosamine	caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]	20360939
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of CDKN2A mRNA	17602206
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of CDKN2A mRNA	19642983\|2036093
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased methylation of CDKN2A promoter	19642983
C007379	diethyl phthalate	[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA	28013214
C025605	diisobutyl phthalate	[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA	28013214
C012125	diisononyl phthalate	[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA	28013214
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Butyric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"CDKN2A gene polymorphism results in increased susceptibility to 9,10-Dimethyl-1,2-benzanthracene"	11544531
D015127	9,10-Dimethyl-1,2-benzanthracene	"Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]"	24792773
D015127	9,10-Dimethyl-1,2-benzanthracene	"Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]"	24792773
D019813	1,2-Dimethylhydrazine	"1,2-Dimethylhydrazine results in increased expression of CDKN2A mRNA"	26388957
D019813	1,2-Dimethylhydrazine	"1,2-Dimethylhydrazine results in increased expression of CDKN2A protein"	26388957
D019813	1,2-Dimethylhydrazine	"[NFE2L2 protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in increased expression of CDKN2A mRNA"	26388957
D019813	1,2-Dimethylhydrazine	"sulforafan inhibits the reaction [[NFE2L2 protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in increased expression of CDKN2A mRNA]"	26388957
D019813	1,2-Dimethylhydrazine	"sulforafan promotes the reaction [1,2-Dimethylhydrazine results in increased expression of CDKN2A mRNA]"	26388957
D019813	1,2-Dimethylhydrazine	"sulforafan promotes the reaction [1,2-Dimethylhydrazine results in increased expression of CDKN2A protein]"	26388957
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of CDKN2A mRNA	15138612
D004147	Dioxins	3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of CDKN2A mRNA]	15111621
D004147	Dioxins	3'-methoxy-4'-nitroflavone inhibits the reaction [Dioxins results in decreased expression of CDKN2A protein]	15111621
D004147	Dioxins	AHR protein affects the reaction [Dioxins results in decreased expression of CDKN2A mRNA]	15111621
D004147	Dioxins	Dioxins results in decreased expression of CDKN2A mRNA	15111621
D004147	Dioxins	Dioxins results in decreased expression of CDKN2A protein	15111621
D004147	Dioxins	Dioxins results in increased methylation of CDKN2A promoter	15111621
C067311	docetaxel	docetaxel results in decreased expression of CDKN2A protein	16797627
D004317	Doxorubicin	Doxorubicin results in increased expression of CDKN2A mRNA	16705698
D004317	Doxorubicin	Doxorubicin results in increased expression of CDKN2A protein	24902966
D004317	Doxorubicin	Doxorubicin results in increased expression of CDKN2A protein alternative form	24902966
D004317	Doxorubicin	Quercetin inhibits the reaction [Doxorubicin results in increased expression of CDKN2A protein]	24902966
D004317	Doxorubicin	Quercetin inhibits the reaction [Doxorubicin results in increased expression of CDKN2A protein alternative form]	24902966
D004365	Drugs, Chinese Herbal	"Drugs, Chinese Herbal results in increased expression of CDKN2A protein"	23239598
C118739	entinostat	[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene	21224363
C118739	entinostat	[Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA	21224363
C045651	epigallocatechin gallate	epigallocatechin gallate results in decreased metabolism of CDKN2A promoter	16037419
C045651	epigallocatechin gallate	epigallocatechin gallate results in decreased methylation of CDKN2A gene	17683969
C045651	epigallocatechin gallate	epigallocatechin gallate results in decreased methylation of CDKN2A promoter	14633667
C045651	epigallocatechin gallate	epigallocatechin gallate results in increased expression of CDKN2A mRNA	14633667
C045651	epigallocatechin gallate	epigallocatechin gallate results in increased expression of CDKN2A protein	17683969
D005038	Ethylnitrosourea	CDKN2A gene mutant form results in increased susceptibility to Ethylnitrosourea	17943659
D005038	Ethylnitrosourea	Ethylnitrosourea results in decreased expression of CDKN2A	21154115
D005038	Ethylnitrosourea	Phytic Acid inhibits the reaction [Ethylnitrosourea results in decreased expression of CDKN2A]	21154115
D005047	Etoposide	[CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]	21526190\|2152619
D005047	Etoposide	[CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]	21526190\|2152619
D005047	Etoposide	cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]	23690541
D005047	Etoposide	Etoposide results in increased expression of CDKN2A mRNA	23690541
D005047	Etoposide	mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]	23690541
D005047	Etoposide	salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]	23690541
D015025	Zearalenone	Zearalenone results in decreased expression of CDKN2A mRNA	28965971
D005273	Fenbendazole	Fenbendazole results in decreased expression of CDKN2A protein	22659510
D005273	Fenbendazole	Fenbendazole results in increased expression of CDKN2A protein	23411599
D005273	Fenbendazole	Fenbendazole results in increased methylation of CDKN2A gene	22659510
C000499	ferric oxide	ferric oxide analog results in decreased expression of CDKN2A mRNA	24525745
D015073	2-Acetylaminofluorene	[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased expression of CDKN2A mRNA	16317707
D015073	2-Acetylaminofluorene	[2-Acetylaminofluorene co-treated with Diethylnitrosamine] results in increased expression of CDKN2A protein	16317707
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of CDKN2A mRNA	19167416\|2221319
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased methylation of CDKN2A gene	18204080
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased methylation of CDKN2A promoter	20188851
D005472	Fluorouracil	Fluorouracil results in decreased expression of CDKN2A protein	17982676
D005473	Fluoxetine	Fluoxetine results in increased expression of CDKN2A mRNA	21497159
D005492	Folic Acid	Folic Acid affects the methylation of CDKN2A promoter	16646054
D005492	Folic Acid	MTHFR gene polymorphism affects the reaction [Folic Acid affects the methylation of CDKN2A promoter]	16646054
D005492	Folic Acid	Folic Acid affects the expression of CDKN2A mRNA	17585020
D005492	Folic Acid	Folic Acid affects the methylation of CDKN2A promoter	17585020
C069837	fullerene C60	fullerene C60 analog results in increased expression of CDKN2A protein	20045429
C056933	fumonisin B1	fumonisin B1 results in increased expression of CDKN2A mRNA	16221962
C039281	furan	furan results in increased expression of CDKN2A mRNA	20562052\|2207923
D024504	gamma-Tocopherol	gamma-Tocopherol results in decreased expression of CDKN2A protein	12368234
D005938	Glucocorticoids	Glucocorticoids results in increased expression of CDKN2A protein	15034294
D005947	Glucose	Glucose results in increased expression of CDKN2A protein alternative form	23494737
D005947	Glucose	SIRT3 protein inhibits the reaction [Glucose results in increased expression of CDKN2A protein alternative form]	23494737
C004312	glycidol	glycidol results in increased expression of CDKN2A mRNA	24915197
C511402	Grape Seed Proanthocyanidins	Grape Seed Proanthocyanidins results in increased expression of CDKN2A mRNA	22749965
C511402	Grape Seed Proanthocyanidins	Grape Seed Proanthocyanidins results in increased expression of CDKN2A protein	22749965
D005937	Glucaric Acid	"Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]"	24792773
D005937	Glucaric Acid	"Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]"	24792773
D005937	Glucaric Acid	"Glucaric Acid inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]"	24792773
C500810	GW8510	GW8510 results in increased expression of CDKN2A mRNA	22242153
D006247	Harmine	Harmine results in decreased expression of CDKN2A mRNA	25751815
D006247	Harmine	Harmine results in decreased expression of CDKN2A protein	25751815
C089796	hexabromocyclododecane	hexabromocyclododecane results in decreased expression of CDKN2A mRNA	19027819
D006581	Hexachlorobenzene	Hexachlorobenzene results in increased methylation of CDKN2A promoter alternative form	26431795
D017313	Fenretinide	Fenretinide results in increased expression of CDKN2A protein	16570282
D006830	Hydralazine	Hydralazine results in decreased methylation of CDKN2A promoter	15862127
D006830	Hydralazine	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]	18504326
D006830	Hydralazine	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]	18504326
D006852	Hydrochlorothiazide	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]	18504326
D006852	Hydrochlorothiazide	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]	18504326
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of CDKN2A protein	21179406
D006861	Hydrogen Peroxide	Hydrogen Peroxide promotes the reaction [MAPT results in increased expression of CDKN2A protein]	28526263
D006918	Hydroxyurea	Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene]	17686055
D006918	Hydroxyurea	Hydroxyurea inhibits the reaction [decitabine results in decreased methylation of CDKN2A gene]	17686055
D006918	Hydroxyurea	Hydroxyurea results in increased expression of CDKN2A protein	10961388
D000068877	Imatinib Mesylate	Imatinib Mesylate results in increased expression of CDKN2A mRNA	21536647
C051890	irinotecan	CDKN2A results in increased susceptibility to irinotecan	22898888
C051890	irinotecan	irinotecan affects the expression of CDKN2A protein	22898888
C051890	irinotecan	irinotecan results in decreased expression of CDKN2A mRNA	16432164
C051890	irinotecan	[irinotecan co-treated with SPARC protein] results in increased expression of CDKN2A mRNA	20164124
C051890	irinotecan	[irinotecan co-treated with SPARC protein] results in increased expression of CDKN2A protein	20164124
D017953	Isocyanates	Isocyanates results in increased expression of CDKN2A protein	20685613
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of CDKN2A mRNA	26830473
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of CDKN2A mRNA	24796395
C008261	lead acetate	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA	12634122
D008012	Lidocaine	Lidocaine affects the expression of CDKN2A mRNA	18931217
C018584	linalool	linalool results in increased expression of CDKN2A mRNA	26703569
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of CDKN2A mRNA	25613284
D018021	Lithium Chloride	Lithium Chloride results in increased expression of CDKN2A mRNA	23527032
D058185	Magnetite Nanoparticles	Magnetite Nanoparticles results in decreased expression of CDKN2A mRNA	24525745
D009637	Masoprocol	Masoprocol results in decreased methylation of CDKN2A promoter	18164318
D009637	Masoprocol	Masoprocol results in increased expression of CDKN2A mRNA	18164318
D009637	Masoprocol	Masoprocol results in increased expression of CDKN2A protein	18164318
C042720	mercuric bromide	mercuric bromide results in increased expression of CDKN2A mRNA	26272509
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA"	27188386
D019216	Metals, Heavy	"Metals, Heavy results in increased expression of CDKN2A mRNA"	12773770
D008713	Methimazole	Methimazole results in increased expression of CDKN2A mRNA	22504374
C013598	methoxyacetic acid	"6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide inhibits the reaction [methoxyacetic acid results in increased expression of CDKN2A protein]"	21573189
C013598	methoxyacetic acid	methoxyacetic acid results in increased expression of CDKN2A protein	21573189
D008731	Methoxychlor	Methoxychlor results in increased expression of CDKN2A mRNA	20829426
C005223	methyleugenol	methyleugenol results in decreased expression of CDKN2A mRNA	26011634
C005223	methyleugenol	methyleugenol results in increased expression of CDKN2A protein	23411599
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of CDKN2A mRNA	20061341
C004925	methylmercuric chloride	methylmercuric chloride results in decreased methylation of CDKN2A promoter	19636072
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of CDKN2A protein	22918959
D015655	1-Methyl-4-phenylpyridinium	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of CDKN2A mRNA]	12710931
C008493	methylselenic acid	methylselenic acid promotes the reaction [CDKN2A protein binds to CDK4 protein binds to CCND1 protein]	17847021
C008493	methylselenic acid	methylselenic acid promotes the reaction [CDKN2A protein binds to CDK6 protein]	17847021
C008493	methylselenic acid	methylselenic acid results in decreased activity of [CDKN2A protein binds to CDK4 protein binds to CCND1 protein]	17847021
C008493	methylselenic acid	methylselenic acid results in decreased activity of [CDKN2A protein binds to CDK6 protein]	17847021
C008493	methylselenic acid	methylselenic acid results in increased expression of CDKN2A protein	17847021
C502486	methyl triclosan	methyl triclosan results in increased expression of CDKN2A mRNA alternative form	26970259
D015741	Metribolone	Metribolone results in increased expression of CDKN2A protein	23272087
C063855	microcystin RR	microcystin RR results in decreased expression of CDKN2A protein	19111056
C066851	mithramycin A	mithramycin A inhibits the reaction [TGFB1 protein results in increased expression of CDKN2A mRNA alternative form]	23940569
C066851	mithramycin A	mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]	23690541
C568376	MT19c compound	MT19c compound results in increased expression of CDKN2A protein	21803404
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of CDKN2A mRNA"	22076105
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of CDKN2A mRNA"	15585362\|2363490
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of CDKN2A mRNA"	25554681\|2911286
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of CDKN2A mRNA alternative form"	29112861
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of CDKN2A protein"	29112861
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of CDKN2A protein alternative form"	29112861
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased methylation of CDKN2A exon"	29112861
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased mutagenesis of CDKN2A gene alternative form"	29112861
D009532	Nickel	Nickel results in decreased expression of CDKN2A	22410783
C022838	nickel chloride	nickel chloride affects the expression of CDKN2A mRNA	22546817
C028007	nickel monoxide	nickel monoxide results in increased expression of CDKN2A mRNA	19167457
C017557	nickel subsulfide	nickel subsulfide results in decreased expression of CDKN2A mRNA	21565688
C017557	nickel subsulfide	nickel subsulfide results in increased methylation of CDKN2A gene	21565688
C017558	nickel sulfide	nickel sulfide results in increased methylation of CDKN2A gene	11984000
C090577	N,N'-bis(salicylideneamino)ethane-manganese(II)	"N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [SOD2 gene mutant form results in increased expression of CDKN2A protein]"	21195081
C025589	ochratoxin A	ochratoxin A results in increased expression of CDKN2A protein	28286205
C000594117	ON123300	ON123300 results in decreased expression of CDKN2A mRNA	26873845
C000594117	ON123300	ON123300 results in decreased expression of CDKN2A mRNA alternative form	26873845
C500026	palbociclib	CDKN2A gene modified form affects the susceptibility to palbociclib	24495407
C500026	palbociclib	CDKN2A gene mutant form affects the susceptibility to palbociclib	24495407
C500026	palbociclib	CDKN2A gene mutant form results in increased susceptibility to palbociclib	21278246
C500026	palbociclib	CDKN2A protein affects the susceptibility to palbociclib	24495407
C500026	palbociclib	[CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib	20534551
C500026	palbociclib	CDKN2A protein results in decreased susceptibility to palbociclib	21278246\|2271160
C500026	palbociclib	[CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib	24098593
C500026	palbociclib	CDKN2A gene mutant form results in increased susceptibility to palbociclib	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein	24098593
C500026	palbociclib	[CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein	24098593
C500026	palbociclib	CDKN2A protein affects the susceptibility to palbociclib	23898052
D010278	Parathion	Parathion results in increased expression of CDKN2A mRNA	17390078
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in increased expression of CDKN2A mRNA	22425687\|2586842
D010634	Phenobarbital	[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of CDKN2A protein	15082532
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of CDKN2A mRNA	26272509
D010833	Phytic Acid	Phytic Acid affects the methylation of CDKN2A promoter	21154115
D010833	Phytic Acid	Phytic Acid inhibits the reaction [Ethylnitrosourea results in decreased expression of CDKN2A]	21154115
D010862	Pilocarpine	Pilocarpine results in decreased expression of CDKN2A mRNA	17971868
D010862	Pilocarpine	Pilocarpine results in increased expression of CDKN2A mRNA	17971868
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CDKN2A mRNA	19710929
C006253	pirinixic acid	pirinixic acid results in increased expression of CDKN2A mRNA	16221962
C006253	pirinixic acid	PPARA protein affects the reaction [pirinixic acid results in increased expression of CDKN2A mRNA]	16221962
D010894	Piroxicam	Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]	12189186
D010894	Piroxicam	Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]	12189186
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls results in decreased methylation of CDKN2A promoter	19636072
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of CDKN2A mRNA	23940686
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of CDKN2A protein	23718831
D011241	Prednisone	Prednisone results in increased expression of CDKN2A protein	15034294
D011342	Procainamide	Procainamide results in increased expression of CDKN2A protein	17938735
D011398	Promethazine	Promethazine results in decreased expression of CDKN2A mRNA	26011634
D011441	Propylthiouracil	Propylthiouracil results in increased expression of CDKN2A mRNA	22504374\|2478091
C014175	pyrazolo(3,4-d)pyrimidine	"pyrazolo(3,4-d)pyrimidine analog affects the expression of CDKN2A mRNA"	21152443
C010423	pyrithione zinc	pyrithione zinc affects the expression of CDKN2A protein	21557991
D011794	Quercetin	[Cisplatin co-treated with Quercetin] results in increased expression of CDKN2A mRNA	27514524
D011794	Quercetin	Quercetin results in decreased expression of CDKN2A mRNA	23727915
D011794	Quercetin	Quercetin results in decreased methylation of CDKN2A promoter	18974642
D011794	Quercetin	Quercetin inhibits the reaction [Doxorubicin results in increased expression of CDKN2A protein]	24902966
D011794	Quercetin	Quercetin inhibits the reaction [Doxorubicin results in increased expression of CDKN2A protein alternative form]	24902966
C037219	quinoline	quinoline analog results in decreased methylation of CDKN2A promoter	19417133
C037219	quinoline	quinoline analog results in increased expression of CDKN2A mRNA	19417133
C037219	quinoline	quinoline analog results in increased expression of CDKN2A protein	19417133
D011886	Radon	Radon results in increased methylation of CDKN2A promoter	16902270
D012110	Reserpine	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]	18504326
D012110	Reserpine	[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]	18504326
C059514	resveratrol	PARP1 protein affects the reaction [resveratrol results in increased expression of CDKN2A protein]	25533949
C059514	resveratrol	resveratrol results in decreased expression of CDKN2A mRNA	17804521
C059514	resveratrol	resveratrol results in increased expression of CDKN2A protein	25533949
C551539	S110 compound	S110 compound results in decreased methylation of CDKN2A gene	17616700
C551539	S110 compound	S110 compound results in increased expression of CDKN2A	17616700
C039961	S-(1,2-dichlorovinyl)cysteine	"S-(1,2-dichlorovinyl)cysteine results in decreased expression of CDKN2A protein"	16495211
C496827	salubrinal	salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]	23690541
C410733	scriptaid	[[decitabine co-treated with scriptaid] affects the methylation of CDKN2A promoter] which affects the expression of CDKN2A mRNA	18813790\|1881379
D012835	Silver Nitrate	Silver Nitrate results in increased expression of CDKN2A mRNA	22831968
D019821	Simvastatin	Simvastatin results in increased expression of CDKN2A protein	18804536
C009277	sodium arsenate	sodium arsenate results in decreased expression of CDKN2A mRNA	11825526
C009277	sodium arsenate	sodium arsenate results in increased methylation of CDKN2A gene	11825526
C017947	sodium arsenite	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA	12634122
C017947	sodium arsenite	sodium arsenite results in decreased expression of CDKN2A mRNA	11825526\|2182045
C017947	sodium arsenite	sodium arsenite results in decreased expression of CDKN2A mRNA alternative form	24816914
C017947	sodium arsenite	sodium arsenite results in decreased expression of CDKN2A protein alternative form	24816914
C017947	sodium arsenite	sodium arsenite results in increased expression of CDKN2A mRNA	12016162\|1263412
C017947	sodium arsenite	sodium arsenite results in increased methylation of CDKN2A gene	11825526
C017947	sodium arsenite	CDKN2A mutant form inhibits the reaction [sodium arsenite results in increased expression of and affects the localization of RBL2 protein]	23890198
C017947	sodium arsenite	sodium arsenite affects the expression of CDKN2A mRNA	16507464
C017947	sodium arsenite	[sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CDKN2A mRNA	16368122
C017947	sodium arsenite	sodium arsenite promotes the reaction [EHMT2 protein binds to CDKN2A promoter]	22733434
C017947	sodium arsenite	sodium arsenite results in decreased expression of CDKN2A mRNA	22733434
C017947	sodium arsenite	sodium arsenite results in increased expression of CDKN2A mRNA	23890198
C017947	sodium arsenite	sodium arsenite results in increased expression of CDKN2A protein	23890198
C017947	sodium arsenite	sodium arsenite results in increased expression of CDKN2A protein alternative form	25787150
C017947	sodium arsenite	sodium arsenite results in decreased expression of CDKN2A mRNA	16876216
C017947	sodium arsenite	sodium arsenite results in decreased expression of CDKN2A protein	16876216
C016104	sodium bichromate	Benzo(a)pyrene affects the reaction [sodium bichromate results in decreased expression of CDKN2A mRNA]	22613061
C016104	sodium bichromate	sodium bichromate results in decreased expression of CDKN2A mRNA	22613061
D012969	Sodium Fluoride	Sodium Fluoride results in decreased expression of CDKN2A mRNA	27862939
D018038	Sodium Selenite	Sodium Selenite results in increased expression of CDKN2A protein	25204997
D053260	Soot	Soot results in increased methylation of CDKN2A promoter	11872642
D013148	Spironolactone	Spironolactone inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]	18504326
D013148	Spironolactone	Spironolactone inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]	18504326
D013311	Streptozocin	NTN1 protein inhibits the reaction [Streptozocin results in increased expression of CDKN2A mRNA]	29059224
D013311	Streptozocin	NTN1 protein inhibits the reaction [Streptozocin results in increased expression of CDKN2A protein]	29059224
D013311	Streptozocin	Streptozocin results in increased expression of CDKN2A mRNA	29059224
D013311	Streptozocin	Streptozocin results in increased expression of CDKN2A protein	29059224
C016766	sulforafan	"sulforafan inhibits the reaction [[NFE2L2 protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in increased expression of CDKN2A mRNA]"	26388957
C016766	sulforafan	"sulforafan promotes the reaction [1,2-Dimethylhydrazine results in increased expression of CDKN2A mRNA]"	26388957
C016766	sulforafan	"sulforafan promotes the reaction [1,2-Dimethylhydrazine results in increased expression of CDKN2A protein]"	26388957
D013458	Sulfur Dioxide	[Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of CDKN2A mRNA	19408242
D013458	Sulfur Dioxide	[Sulfur Dioxide co-treated with Benzo(a)pyrene] results in increased expression of CDKN2A protein	19408242
D013458	Sulfur Dioxide	Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in decreased expression of CDKN2A mRNA]	20064080
D013458	Sulfur Dioxide	Sulfur Dioxide promotes the reaction [Benzo(a)pyrene results in decreased expression of CDKN2A protein]	20064080
D013458	Sulfur Dioxide	Sulfur Dioxide results in decreased expression of CDKN2A mRNA	19408242\|1943469
D013458	Sulfur Dioxide	Sulfur Dioxide results in decreased expression of CDKN2A protein	19434695\|2006408
D013458	Sulfur Dioxide	Sulfur Dioxide results in increased expression of CDKN2A protein	19408242
D013467	Sulindac	Sulindac inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]	12189186
D000952	Antigens, Polyomavirus Transforming	"Antigens, Polyomavirus Transforming results in increased expression of CDKN2A mRNA"	26680231
C011363	terephthalic acid	terephthalic acid results in decreased expression of CDKN2A protein	16896691
C045037	testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	testosterone-3-carboxymethyloxime-bovine serum albumin conjugate affects the expression of CDKN2A mRNA	20189893
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CDKN2A mRNA	17070097\|1725763
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CDKN2A protein	17070097
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in decreased expression of CDKN2A mRNA	21167638
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in decreased expression of CDKN2A protein	21167638
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of CDKN2A mRNA	24058054
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of CDKN2A mRNA	22298810
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased methylation of CDKN2A promoter alternative form	26431795
D013755	Tetradecanoylphorbol Acetate	[arsenic trioxide co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CDKN2A mRNA	18922899
D013755	Tetradecanoylphorbol Acetate	[sodium arsenite co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CDKN2A mRNA	16368122
D013853	Thioacetamide	Thioacetamide affects the expression of CDKN2A mRNA	26011634
D013853	Thioacetamide	Thioacetamide affects the localization of CDKN2A protein	22659510
D013853	Thioacetamide	Thioacetamide results in decreased expression of CDKN2A mRNA	22659510
D013853	Thioacetamide	Thioacetamide results in increased expression of CDKN2A protein	22659510\|2341159
D013881	Thioridazine	Thioridazine results in increased expression of CDKN2A protein	21035837
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of CDKN2A mRNA	17070097
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of CDKN2A protein	17070097
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased methylation of CDKN2A promoter	12117769\|1937581
D014118	Toxins, Biological	"Toxins, Biological affects the expression of CDKN2A mRNA"	19682533
D014212	Tretinoin	Tretinoin results in decreased expression of CDKN2A mRNA	16494909
D014212	Tretinoin	Tretinoin results in increased expression of CDKN2A mRNA	17138961
C012589	trichostatin A	[decitabine co-treated with trichostatin A] affects the expression of CDKN2A protein	17019711
C012589	trichostatin A	[decitabine co-treated with trichostatin A] affects the methylation of CDKN2A promoter	18069755
C012589	trichostatin A	[[decitabine co-treated with trichostatin A] affects the methylation of CDKN2A promoter] which affects the expression of CDKN2A mRNA	18813790\|1881379
C012589	trichostatin A	trichostatin A results in decreased expression of CDKN2A mRNA	19606018
C012589	trichostatin A	trichostatin A results in increased expression of CDKN2A mRNA	23770000
C012589	trichostatin A	trichostatin A results in increased expression of CDKN2A protein	23770000
D014260	Triclosan	Triclosan results in decreased expression of CDKN2A mRNA alternative form	26970259
D014260	Triclosan	Triclosan results in increased methylation of CDKN2A gene	26970259
C113580	U 0126	U 0126 inhibits the reaction [arsenite results in decreased expression of CDKN2A protein]	21040761
C000602704	UF010 compound	UF010 compound results in increased activity of CDKN2A protein	25699604
D014520	Urethane	CDKN2A gene polymorphism results in increased susceptibility to Urethane	11544531
D014520	Urethane	Urethane results in decreased expression of CDKN2A mRNA	12117781
D014520	Urethane	Urethane results in decreased expression of CDKN2A protein	25168426
D014635	Valproic Acid	Valproic Acid affects the expression of CDKN2A mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of CDKN2A mRNA	19101580\|2258053
D014635	Valproic Acid	Valproic Acid results in increased methylation of CDKN2A gene	29154799
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of CDKN2A promoter	26410583
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of CDKN2A gene	25560391
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of CDKN2A promoter	11872642
D014750	Vincristine	CDKN2A protein results in increased susceptibility to Vincristine	16786135
C030852	vinorelbine	vinorelbine results in decreased expression of CDKN2A protein	17904787
D014752	Vinyl Chloride	CDKN2A polymorphism affects the susceptibility to Vinyl Chloride	24464562
D014800	Vitallium	Vitallium analog results in increased expression of CDKN2A mRNA	23825117
D009536	Niacinamide	"Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]"	24792773
D009536	Niacinamide	"Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]"	24792773
D009536	Niacinamide	"Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]"	24792773
C024534	vitamin k5	vitamin k5 results in increased expression of CDKN2A mRNA	16010434
D024482	Vitamin K 2	Vitamin K 2 results in increased expression of CDKN2A mRNA	16010434
D024483	Vitamin K 3	Vitamin K 3 results in increased expression of CDKN2A mRNA	16010434
D015215	Zidovudine	Zidovudine results in increased expression of CDKN2A mRNA	16797627
D015215	Zidovudine	Zidovudine results in increased expression of CDKN2A protein	16797627
D015215	Zidovudine	Zidovudine affects the expression of CDKN2A protein	18389896

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003723	RNA binding	-	HDA	22681889
GO:0004861	cyclin-dependent protein serine/threonine kinase inhibitor activity	-	IBA	21873635
GO:0004861	cyclin-dependent protein serine/threonine kinase inhibitor activity	-	IDA	7739547 8259215
GO:0005515	protein binding	-	IPI	9751050 11278317 15232106 17353931 17517622 17658461 17909018 17955473 19149898 21988832 23455922 23602568 24855949 26496610
GO:0019901	protein kinase binding	-	IPI	8259215
GO:0051059	NF-kappaB binding	-	IDA	10353611

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000082	G1/S transition of mitotic cell cycle	-	IDA	10208428
GO:0001953	negative regulation of cell-matrix adhesion	-	IMP	10205165
GO:0007050	cell cycle arrest	-	IDA	15149599
GO:0007050	cell cycle arrest	-	IMP	16243918
GO:0007265	Ras protein signal transduction	-	IEP	9054499
GO:0008285	negative regulation of cell proliferation	-	IDA	15149599
GO:0008285	negative regulation of cell proliferation	-	IMP	7603984 16243918 16901784
GO:0030308	negative regulation of cell growth	-	IDA	10208428
GO:0031658	negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	-	TAS	-
GO:0032088	negative regulation of NF-kappaB transcription factor activity	-	IDA	10353611
GO:0034393	positive regulation of smooth muscle cell apoptotic process	-	ISS	20381282
GO:0035986	senescence-associated heterochromatin focus assembly	-	IMP	16901784
GO:0042326	negative regulation of phosphorylation	-	IDA	8259215 10208428
GO:0045736	negative regulation of cyclin-dependent protein serine/threonine kinase activity	-	IDA	7739547 8259215
GO:0045892	negative regulation of transcription, DNA-templated	-	IMP	16901784
GO:0090398	cellular senescence	-	IMP	16243918
GO:0090399	replicative senescence	-	IMP	14720514
GO:2000111	positive regulation of macrophage apoptotic process	-	ISS	20381282
GO:2000774	positive regulation of cellular senescence	-	IMP	16901784

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005634	nucleus	-	IBA	21873635
GO:0005634	nucleus	-	IDA	16243918
GO:0005737	cytoplasm	-	IDA	16243918
GO:0005829	cytosol	-	TAS	-
GO:0035985	senescence-associated heterochromatin focus	-	IDA	16901784

KEGG ID	KEGG Term
hsa04110	Cell cycle
hsa04115	p53 signaling pathway
hsa05200	Pathways in cancer
hsa05212	Pancreatic cancer
hsa05214	Glioma
hsa05218	Melanoma
hsa05219	Bladder cancer
hsa05220	Chronic myeloid leukemia
hsa05223	Non-small cell lung cancer

Reactome ID	Reactome Term	Evidence
R-HSA-1640170	Cell Cycle	TAS
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2262752	Cellular responses to stress	TAS
R-HSA-2559580	Oxidative Stress Induced Senescence	TAS
R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	TAS
R-HSA-2559583	Cellular Senescence	TAS
R-HSA-2559585	Oncogene Induced Senescence	TAS
R-HSA-2990846	SUMOylation	TAS
R-HSA-3108214	SUMOylation of DNA damage response and repair proteins	TAS
R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	TAS
R-HSA-3232118	SUMOylation of transcription factors	TAS
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-453279	Mitotic G1-G1/S phases	TAS
R-HSA-5633007	Regulation of TP53 Activity	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-6804757	Regulation of TP53 Degradation	TAS
R-HSA-6806003	Regulation of TP53 Expression and Degradation	TAS
R-HSA-69231	Cyclin D associated events in G1	TAS
R-HSA-69236	G1 Phase	TAS
R-HSA-69278	Cell Cycle, Mitotic	TAS
R-HSA-69541	Stabilization of p53	TAS
R-HSA-69563	p53-Dependent G1 DNA Damage Response	TAS
R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	TAS
R-HSA-69615	G1/S DNA Damage Checkpoints	TAS
R-HSA-69620	Cell Cycle Checkpoints	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8878159	Transcriptional regulation by RUNX3	TAS
R-HSA-8941858	Regulation of RUNX3 expression and activity	TAS
R-HSA-8953897	Cellular responses to external stimuli	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
27987577	Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs. (2016 Dec)	Jiang J	Lung Cancer
17409975	Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. (2006 Nov)	Lam DC	J Thorac Oncol
25911935	[Genetic aspects of pancreatic cancer]. (2014)	Grigor'eva IN	Eksp Klin Gastroenterol
21380558	Methylation analysis of cancer-related genes in non-neoplastic cells from patients with oral squamous cell carcinoma. (2011 Nov)	de Freitas Cordeiro-Silva M	Mol Biol Rep
22154617	Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer. (2011 Nov)	Tan C	Arch Med Res
16470878	Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. (2006 Apr)	O'Regan EM	Head Neck
24436120	Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. (2014 Aug 15)	Lim AM	Int J Cancer
24706381	Combined P16 and human papillomavirus testing predicts head and neck cancer survival. (2014 Nov 15)	Salazar CR	Int J Cancer
12918069	Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. (2003 Oct 10)	Jarmalaite S	Int J Cancer
23976908	Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing - a longitudinal study in females. (2013 Oct)	Reece AS	J Clin Med Res
16888680	[Familial pancreatic cancer]. (2006)	Zalatnai A	Magy Onkol
21347282	Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. (2011 Feb 10)	Lettre G	PLoS Genet
18824881	Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. (2008)	Ishida M	Pancreatology
29355614	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. (2018 Jan 30)	Solomon B	Semin Cancer Biol
26834999	Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence. (2015)	Krishnan N	F1000Res
26164066	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep)	Preusser M	Eur J Cancer
28559012	Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient. (2017 Jun)	Wang SJ	Oral Oncol
28256572	Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. (2017 Jun)	Yoshida A	Mod Pathol
22216278	Large scale association analysis identifies three susceptibility loci for coronary artery disease. (2011)	Saade S	PLoS One
12185599	A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression. (2002 Aug 29)	Zhang Z	Oncogene
24329809	Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: a longitudinal study. (2014 Apr)	Reece AS	J Clin Pharm Ther
16162302	Treatment of familial pancreatic cancer and its precursors. (2005 Oct)	Hruban RH	Curr Treat Options Gastroenterol
23213974	Etiology and oncogenesis of pancreatic carcinoma. (2012 Sep)	Dobrila-Dintinjana R	Coll Antropol
19396864	CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. (2009 Jul)	Guled M	Genes Chromosomes Cancer
18349282	DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. (2008 Mar)	Feng Q	Cancer Epidemiol Biomarkers Prev
14871814	Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. (2004 Feb 1)	Iacobuzio-Donahue CA	Cancer Res
19375815	p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. (2010 Jan)	Andujar P	Lung Cancer
17711772	Significance and mechanism of microsatellite instability in laryngeal squamous cell carcinoma. (2007 Jun)	Zhigang H	J Otolaryngol
26900290	Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. (2016 Feb 21)	Sasaki Y	World J Gastroenterol
26873401	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. (2016 May)	Sawada G	Gastroenterology
18549475	Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. (2008 Jun 12)	Blons H	BMC Med Genomics
25631445	Comprehensive genomic characterization of head and neck squamous cell carcinomas. (2015 Jan 29)	-	Nature
24077454	CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. (2013 Nov)	Tam KW	J Thorac Oncol
29197760	Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. (2018 Feb)	Callahan CL	Environ Res
19150414	Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. (2009 Mar-Jun)	Landi S	Mutat Res
25754026	Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. (2015 Mar 10)	Huang T	Sci Rep
25064638	Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. (2014 Nov)	Potrony M	J Am Acad Dermatol
28927526	Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles. (2017 Jul)	Cardoso MFS	Mutat Res
19351817	Genetic mutations associated with cigarette smoking in pancreatic cancer. (2009 Apr 15)	Blackford A	Cancer Res
29030599	Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. (2017 Oct 13)	Joshi PK	Nat Commun
25280564	Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. (2014 Dec)	Buas MF	Carcinogenesis
22948376	p16 (INK4a) has clinicopathological and prognostic impact on oropharynx and larynx squamous cell carcinoma. (2012 Dec)	Silva SD	Braz J Med Biol Res
19807915	Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. (2009 Oct 6)	Taioli E	BMC Cancer
29335443	Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. (2018 Jan 15)	Nahar R	Nat Commun
24451080	Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients. (2013)	Szymanowska-Narloch A	Adv Med Sci
22316562	[High-risk human papilloma virus associated oropharynx squamous cell carcinomas: clinical, biological implications and therapeutical perspectives]. (2012 Feb)	Guihard S	Cancer Radiother
22776031	Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke. (2012 Jul 9)	Hacke W	BMC Med
21734801	Molecular biology of pancreatic cancer. (2011 Jun 28)	Zavoral M	World J Gastroenterol
24365123	Association of polymorphisms on chromosome 9p21.3 region with increased susceptibility of abdominal aortic aneurysm in a Chinese Han population. (2014 Apr)	Wei Y	J Vasc Surg
24278325	Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. (2013)	Urashima M	PLoS One
24163741	Molecular biology of lung cancer. (2013 Oct)	Cooper WA	J Thorac Dis
11221887	Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. (2001 Feb 1)	Rosas SL	Cancer Res
11291558	The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. (2001)	Chappuis PO	Cancer Invest
17575133	Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. (2007 Jun 15)	Mounawar M	Cancer Res
22412179	Disparate molecular, histopathology, and clinical factors in head and neck squamous cell carcinoma racial groups. (2012 Aug)	Worsham MJ	Otolaryngol Head Neck Surg
21487403	Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. (2011 Apr 26)	Ma YT	Br J Cancer
15390186	Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. (2004 Dec)	Hazra A	Genes Chromosomes Cancer